Clinical trials are the most effective tool for finding breakthrough drug treatments. The first large-scale breast cancer prevention study in 1998, NCABP’s P-1 testShows that by using tamoxifen, healthy women with an increased risk of breast cancer can reduce their risk of breast cancer by nearly 50%.
Even if a better treatment has been proven, Only 5% Patients with breast cancer participate in the trial. This shows how the experiment was misunderstood and the need for education and awareness of its true benefits. Before describing the four most common misconceptions about clinical trials and debunking methods, it’s important to understand the clinical trial process.
How the experiment works
The first stage
This stage is the first time that human beings receive the treatment under study, usually starting from a small group of people who are free of disease. This process usually takes several months, allowing researchers to understand the side effects and safe dosages.
second stage
This stage involves more participants, this time it is for treatment of the disease. As in the first phase, the goal is to determine possible side effects and determine the overall safety of the treatment. This process may take up to several years.
The third stage
This stage expands the scope of participants to people of different regions, genders and races in the world, and all these diseases are targeted for treatment. The goal is to determine whether the treatment being studied is more effective than the other options available. If it proves to be more effective, there is usually enough information to get approval for the drug.
The fourth stage
This stage occurs after the treatment has received regulatory approval, but the premise is that the introduction of the treatment to the market requires additional testing over a longer period of time.
Misunderstanding 1: Clinical trials are invalid
As mentioned earlier, clinical trials are actually the gold standard for treatment research and the most powerful way to improve treatment plans and find potential treatments. A 2018 Learn Shows that 35% of trials that introduce new therapies are successful. This seems to be a small percentage, but when considering the prevalence and elusiveness of cancer, the success rate is impressive.
Tests are not only useful for new therapies, but can also help researchers identify advanced detection and diagnostic strategies that can reduce the overall risk of developing the disease. In addition, doctors can determine whether the side effects exhibited during the trial outweigh the benefits of the overall treatment.
Because the treatments evaluated by the trial need to be studied for no less than 6 years before the FDA considers approval, patients can get treatments that they would not otherwise have access to. They are also prioritized when seeking clinical treatment, so they can receive higher-quality care regardless of whether the results are associated with the specific drug being studied.
In addition to the efficacy of clinical trials in breast cancer research, trials also enjoy a reputation for disease treatment and prevention. This includes actually eradicating harmful diseases such as polio and measles.
Misunderstanding 2: If you start an experiment, you need to participate in the whole process
One of the most common misconceptions about breast cancer clinical trials is that once participants start participating in clinical trials, they must wait until the end of the study. The fact is that if patients are unwilling, researchers cannot force them to participate in research-this violates ethical and medically acceptable regulations. Patients can withdraw from the trial at any time and for any reason, whether for personal reasons, side effects, or lack of results for the treatment being studied.
Before participating in a clinical trial, the patient’s rights in the trial will be outlined in detail, and the clinician will review it point by point, also known as “informed consent.” This includes:
- Benefits and risks associated with experimental and standard treatments.
- The logistics involved include the number of tests performed, the treatment plan, how many visits you need to have with the doctor, and so on.
Regardless of the length of time involved, each participant plays a key role in advancing breast cancer research and will help future generations of cancer patients, and possibly cure them.
Myth 3: If you give a placebo, you won’t get enough care
Breast cancer patients who enter the trial are a win-win situation. If patients receive the treatment under study, they will also receive priority, high-quality care. If the patient receives standard treatment, it is already an approved and effective treatment. The only time they receive a placebo is when, in rare cases, no existing treatment is available. If a placebo is involved in the study, you will be informed of this possibility before participating in the trial.
Receiving a placebo does not mean that patients will not receive high-quality care. In fact, the situation is quite the opposite. As trial participants, patients will receive the same gold standard of care, and their doctors will prioritize their health.
Misunderstanding 4: It is almost impossible to find a suitable clinical trial
Although it is not always easy to find clinical trials in convenient locations, to find new treatments for patients at specific stages and cancer mutations, etc., there are today some tools that can help them find the most relevant clinical trials according to their own circumstances. Location and unique needs.
Through advances in medical technology, patients can find relevant clinical trials by entering their eligibility criteria. This greatly shortens the matching period and saves precious time for cancer patients.
Obviously, clinical trials are very important and have almost no adverse effects on patients. Clinical trials are the safest and most trustworthy way to determine new breast cancer treatments. The more studies that can be conducted, the closer we will be to the complete eradication of breast cancer.Patients looking for clinical trials should look for the following resources American Breast Cancer Association, BreastCancerTrials.org, ClinicalTrials.gov, or NCI And talk to their doctor.
